Transplant center directory

The Blood and Marrow Transplantation Program at Helen DeVos Children's Hospital takes a multidisciplinary approach to transplant. Our program works closely with the other specialties at Helen DeVos Children's Hospital to provide care for adults, children and their families.

This center has been performing allogeneic transplants since 1998 and has been an NMDP/Be The Match transplant center since March 2002.

Corewell Health

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 105 patients.

The actual 1-year survival of these patients is 68.6%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 66.7% and 82.5%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

Corewell Health/Helen DeVos Children's Hospital

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 21 patients.

The actual 1-year survival of these patients is 90.5%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 68.3% and 98.3%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.